Need help finding what you are looking for?
Contact Us
PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1940977
PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1940977
Liquid Biopsy Market Insights, Competitive Landscape, and Market Forecast - 2033
PUBLISHED:
PAGES: 199 Pages
DELIVERY TIME: 2-5 business days
SELECT AN OPTION
The global Liquid Biopsy Market is experiencing remarkable growth, driven by the rising adoption of non-invasive diagnostic technologies and the increasing prevalence of cancer worldwide. Valued at USD 4.1 billion in 2026, the market is expected to reach USD 8.7 billion by 2033, growing at a robust compound annual growth rate (CAGR) of 11.3% during the forecast period. Liquid biopsy, a cutting-edge diagnostic method, allows for the detection of cancer-related biomarkers from body fluids such as blood, urine, and other sources, offering a safer and faster alternative to traditional tissue biopsies.
Liquid biopsies are becoming an essential tool in modern healthcare as they provide real-time insights into tumor genetics, mutations, and disease progression. Unlike conventional methods, they reduce patient discomfort, enable continuous monitoring, and facilitate early intervention, making them an attractive choice for clinicians and patients alike.
Market Insights
The shift towards personalized medicine is a major driver of liquid biopsy adoption. By analyzing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other molecular biomarkers, physicians can design targeted treatment strategies tailored to each patient's unique genetic profile. This precision-based approach improves treatment outcomes, reduces adverse effects, and supports more informed clinical decisions.
Advances in next-generation sequencing (NGS), digital PCR, and other molecular diagnostics have further expanded the capabilities of liquid biopsy, enabling detection at early stages and monitoring of multiple cancer types. Collaborations among biotech companies, research institutions, and hospitals are accelerating innovation and expanding the market landscape.
Market Drivers
Key factors fueling growth in the liquid biopsy market include:
- Increasing Cancer Incidence: Growing cases of lung, breast, prostate, and colorectal cancers are creating demand for early and reliable diagnostic solutions.
- Minimally Invasive Diagnostics: Liquid biopsy offers a safer and less invasive alternative to tissue biopsy, reducing patient risk and improving compliance.
- Technological Advancements: Continuous innovation in biomarker detection and sequencing techniques is enhancing test sensitivity and accuracy.
- Adoption of Precision Medicine: The global emphasis on personalized oncology is driving the use of liquid biopsies for treatment selection, monitoring, and recurrence detection.
- Government Support and Funding: Regulatory approvals and research grants are facilitating the development and commercialization of liquid biopsy technologies.
Business Opportunity
The liquid biopsy market presents significant opportunities for both established industry leaders and emerging innovators. With advancements in biomarker discovery and assay precision, companies can expand their offerings across new clinical applications. Integration with digital health platforms and companion diagnostics further enhances the market potential, enabling data-driven healthcare solutions.
Strategic partnerships, mergers, and acquisitions are helping companies strengthen their technological capabilities and global presence. Market players offering validated, high-quality liquid biopsy assays are well-positioned to capitalize on increasing demand from hospitals, research labs, and diagnostic centers.
Regional Analysis
North America currently leads the global liquid biopsy market, driven by advanced healthcare infrastructure, high awareness of precision medicine, and substantial R&D investment. The U.S. is a major contributor, with widespread adoption of innovative diagnostics and the presence of key biotechnology companies.
Europe is experiencing steady growth, supported by initiatives aimed at improving cancer detection and increasing clinical trial activities in countries such as Germany, the U.K., and France.
The Asia Pacific region is projected to grow rapidly, fueled by rising healthcare expenditure, increasing cancer prevalence, and expanding presence of multinational diagnostic companies. Emerging economies like China, India, and Japan offer significant opportunities for market expansion.
Latin America and the Middle East & Africa are gradually adopting liquid biopsy technologies, driven by growing awareness of non-invasive diagnostics and improvements in healthcare infrastructure.
Key Players
- Guardant Health, Inc.
- Grail (Illumina, Inc.)
- ANGLE plc
- Hoffmann-La Roche Ltd.
- Invitae Corporation
- Myriad Genetics, Inc.
- Qiagen N.V.
- Exact Sciences Corporation
- MDxHealth SA
- Sysmex Inostics
- Biocept, Inc.
- NeoGenomics, Inc.
- Exosome Diagnostics, Inc.
- Personal Genome Diagnostics, Inc.
- Menarini-Silicon Biosystems
- Agena Bioscience, Inc.
- MedGenome Inc.
- Epigenomics AG
- Natera, Inc.
- Vortex Biosciences, Inc.
Market Segmentation
By Biomarker:
- Circulating Tumour Cells
- Circulating Tumour DNA
- Circulating Free DNA
- Circulating Cell Free RNA
- Exomes
- Other
By Source:
- Blood
- Urine
- Other
By Clinical Application:
- Diagnosis & Screening
- Treatment Selection
- Treatment Monitoring
- Recurrence Monitoring
By Indication:
- Lung Cancer
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Other Cancers
- Non-Oncology
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Table of Contents
1. Executive Summary
- 1.1. Global Liquid Biopsy Market Snapshot
- 1.2. Future Projections
- 1.3. Key Market Trends
- 1.4. Regional Snapshot, by Value, 2026
- 1.5. Analyst Recommendations
2. Market Overview
- 2.1. Market Definitions and Segmentations
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
- 2.3. Value Chain Analysis
- 2.4. COVID-19 Impact Analysis
- 2.5. Porter's Fiver Forces Analysis
- 2.6. Impact of Russia-Ukraine Conflict
- 2.7. PESTLE Analysis
- 2.8. Regulatory Analysis
- 2.9. Price Trend Analysis
- 2.9.1. Current Prices and Future Projections, 2025-2033
- 2.9.2. Price Impact Factors
3. Global Liquid Biopsy Market Outlook, 2020-2033
- 3.1. Global Liquid Biopsy Market Outlook, by Biomarker, Value (US$ Bn), 2020-2033
- 3.1.1. Circulating Tumour Cells
- 3.1.2. Circulating Tumour DNA
- 3.1.3. Circulating free DNA
- 3.1.4. Circulating Cell free RNA
- 3.1.5. Exomes
- 3.1.6. Other
- 3.2. Global Liquid Biopsy Market Outlook, by Source, Value (US$ Bn), 2020-2033
- 3.2.1. Blood
- 3.2.2. Urine
- 3.2.3. Other
- 3.3. Global Liquid Biopsy Market Outlook, by Clinical Application , Value (US$ Bn), 2020-2033
- 3.3.1. Diagnosis & Screening
- 3.3.2. Treatment Selection
- 3.3.3. Treatment Monitoring
- 3.3.4. Recurrence Monitoring
- 3.4. Global Liquid Biopsy Market Outlook, by Indication , Value (US$ Bn), 2020-2033
- 3.4.1. Lung Cancer
- 3.4.2. Breast Cancer
- 3.4.3. Prostate Cancer
- 3.4.4. Colorectal Cancer
- 3.4.5. Other Cancers
- 3.4.6. Non-Oncology
- 3.5. Global Liquid Biopsy Market Outlook, by Region, Value (US$ Bn), 2020-2033
- 3.5.1. North America
- 3.5.2. Europe
- 3.5.3. Asia Pacific
- 3.5.4. Latin America
- 3.5.5. Middle East & Africa
4. North America Liquid Biopsy Market Outlook, 2020-2033
- 4.1. North America Liquid Biopsy Market Outlook, by Biomarker, Value (US$ Bn), 2020-2033
- 4.1.1. Circulating Tumour Cells
- 4.1.2. Circulating Tumour DNA
- 4.1.3. Circulating free DNA
- 4.1.4. Circulating Cell free RNA
- 4.1.5. Exomes
- 4.1.6. Other
- 4.2. North America Liquid Biopsy Market Outlook, by Source, Value (US$ Bn), 2020-2033
- 4.2.1. Blood
- 4.2.2. Urine
- 4.2.3. Other
- 4.3. North America Liquid Biopsy Market Outlook, by Clinical Application , Value (US$ Bn), 2020-2033
- 4.3.1. Diagnosis & Screening
- 4.3.2. Treatment Selection
- 4.3.3. Treatment Monitoring
- 4.3.4. Recurrence Monitoring
- 4.4. North America Liquid Biopsy Market Outlook, by Indication , Value (US$ Bn), 2020-2033
- 4.4.1. Lung Cancer
- 4.4.2. Breast Cancer
- 4.4.3. Prostate Cancer
- 4.4.4. Colorectal Cancer
- 4.4.5. Other Cancers
- 4.4.6. Non-Oncology
- 4.5. North America Liquid Biopsy Market Outlook, by Country, Value (US$ Bn), 2020-2033
- 4.5.1. U.S. Liquid Biopsy Market Outlook, by Biomarker, 2020-2033
- 4.5.2. U.S. Liquid Biopsy Market Outlook, by Source, 2020-2033
- 4.5.3. U.S. Liquid Biopsy Market Outlook, by Clinical Application , 2020-2033
- 4.5.4. U.S. Liquid Biopsy Market Outlook, by Indication , 2020-2033
- 4.5.5. Canada Liquid Biopsy Market Outlook, by Biomarker, 2020-2033
- 4.5.6. Canada Liquid Biopsy Market Outlook, by Source, 2020-2033
- 4.5.7. Canada Liquid Biopsy Market Outlook, by Clinical Application , 2020-2033
- 4.5.8. Canada Liquid Biopsy Market Outlook, by Indication , 2020-2033
- 4.6. BPS Analysis/Market Attractiveness Analysis
5. Europe Liquid Biopsy Market Outlook, 2020-2033
- 5.1. Europe Liquid Biopsy Market Outlook, by Biomarker, Value (US$ Bn), 2020-2033
- 5.1.1. Circulating Tumour Cells
- 5.1.2. Circulating Tumour DNA
- 5.1.3. Circulating free DNA
- 5.1.4. Circulating Cell free RNA
- 5.1.5. Exomes
- 5.1.6. Other
- 5.2. Europe Liquid Biopsy Market Outlook, by Source, Value (US$ Bn), 2020-2033
- 5.2.1. Blood
- 5.2.2. Urine
- 5.2.3. Other
- 5.3. Europe Liquid Biopsy Market Outlook, by Clinical Application , Value (US$ Bn), 2020-2033
- 5.3.1. Diagnosis & Screening
- 5.3.2. Treatment Selection
- 5.3.3. Treatment Monitoring
- 5.3.4. Recurrence Monitoring
- 5.4. Europe Liquid Biopsy Market Outlook, by Indication , Value (US$ Bn), 2020-2033
- 5.4.1. Lung Cancer
- 5.4.2. Breast Cancer
- 5.4.3. Prostate Cancer
- 5.4.4. Colorectal Cancer
- 5.4.5. Other Cancers
- 5.4.6. Non-Oncology
- 5.5. Europe Liquid Biopsy Market Outlook, by Country, Value (US$ Bn), 2020-2033
- 5.5.1. Germany Liquid Biopsy Market Outlook, by Biomarker, 2020-2033
- 5.5.2. Germany Liquid Biopsy Market Outlook, by Source, 2020-2033
- 5.5.3. Germany Liquid Biopsy Market Outlook, by Clinical Application , 2020-2033
- 5.5.4. Germany Liquid Biopsy Market Outlook, by Indication , 2020-2033
- 5.5.5. Italy Liquid Biopsy Market Outlook, by Biomarker, 2020-2033
- 5.5.6. Italy Liquid Biopsy Market Outlook, by Source, 2020-2033
- 5.5.7. Italy Liquid Biopsy Market Outlook, by Clinical Application , 2020-2033
- 5.5.8. Italy Liquid Biopsy Market Outlook, by Indication , 2020-2033
- 5.5.9. France Liquid Biopsy Market Outlook, by Biomarker, 2020-2033
- 5.5.10. France Liquid Biopsy Market Outlook, by Source, 2020-2033
- 5.5.11. France Liquid Biopsy Market Outlook, by Clinical Application , 2020-2033
- 5.5.12. France Liquid Biopsy Market Outlook, by Indication , 2020-2033
- 5.5.13. U.K. Liquid Biopsy Market Outlook, by Biomarker, 2020-2033
- 5.5.14. U.K. Liquid Biopsy Market Outlook, by Source, 2020-2033
- 5.5.15. U.K. Liquid Biopsy Market Outlook, by Clinical Application , 2020-2033
- 5.5.16. U.K. Liquid Biopsy Market Outlook, by Indication , 2020-2033
- 5.5.17. Spain Liquid Biopsy Market Outlook, by Biomarker, 2020-2033
- 5.5.18. Spain Liquid Biopsy Market Outlook, by Source, 2020-2033
- 5.5.19. Spain Liquid Biopsy Market Outlook, by Clinical Application , 2020-2033
- 5.5.20. Spain Liquid Biopsy Market Outlook, by Indication , 2020-2033
- 5.5.21. Russia Liquid Biopsy Market Outlook, by Biomarker, 2020-2033
- 5.5.22. Russia Liquid Biopsy Market Outlook, by Source, 2020-2033
- 5.5.23. Russia Liquid Biopsy Market Outlook, by Clinical Application , 2020-2033
- 5.5.24. Russia Liquid Biopsy Market Outlook, by Indication , 2020-2033
- 5.5.25. Rest of Europe Liquid Biopsy Market Outlook, by Biomarker, 2020-2033
- 5.5.26. Rest of Europe Liquid Biopsy Market Outlook, by Source, 2020-2033
- 5.5.27. Rest of Europe Liquid Biopsy Market Outlook, by Clinical Application , 2020-2033
- 5.5.28. Rest of Europe Liquid Biopsy Market Outlook, by Indication , 2020-2033
- 5.6. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Liquid Biopsy Market Outlook, 2020-2033
- 6.1. Asia Pacific Liquid Biopsy Market Outlook, by Biomarker, Value (US$ Bn), 2020-2033
- 6.1.1. Circulating Tumour Cells
- 6.1.2. Circulating Tumour DNA
- 6.1.3. Circulating free DNA
- 6.1.4. Circulating Cell free RNA
- 6.1.5. Exomes
- 6.1.6. Other
- 6.2. Asia Pacific Liquid Biopsy Market Outlook, by Source, Value (US$ Bn), 2020-2033
- 6.2.1. Blood
- 6.2.2. Urine
- 6.2.3. Other
- 6.3. Asia Pacific Liquid Biopsy Market Outlook, by Clinical Application , Value (US$ Bn), 2020-2033
- 6.3.1. Diagnosis & Screening
- 6.3.2. Treatment Selection
- 6.3.3. Treatment Monitoring
- 6.3.4. Recurrence Monitoring
- 6.4. Asia Pacific Liquid Biopsy Market Outlook, by Indication , Value (US$ Bn), 2020-2033
- 6.4.1. Lung Cancer
- 6.4.2. Breast Cancer
- 6.4.3. Prostate Cancer
- 6.4.4. Colorectal Cancer
- 6.4.5. Other Cancers
- 6.4.6. Non-Oncology
- 6.5. Asia Pacific Liquid Biopsy Market Outlook, by Country, Value (US$ Bn), 2020-2033
- 6.5.1. China Liquid Biopsy Market Outlook, by Biomarker, 2020-2033
- 6.5.2. China Liquid Biopsy Market Outlook, by Source, 2020-2033
- 6.5.3. China Liquid Biopsy Market Outlook, by Clinical Application , 2020-2033
- 6.5.4. China Liquid Biopsy Market Outlook, by Indication , 2020-2033
- 6.5.5. Japan Liquid Biopsy Market Outlook, by Biomarker, 2020-2033
- 6.5.6. Japan Liquid Biopsy Market Outlook, by Source, 2020-2033
- 6.5.7. Japan Liquid Biopsy Market Outlook, by Clinical Application , 2020-2033
- 6.5.8. Japan Liquid Biopsy Market Outlook, by Indication , 2020-2033
- 6.5.9. South Korea Liquid Biopsy Market Outlook, by Biomarker, 2020-2033
- 6.5.10. South Korea Liquid Biopsy Market Outlook, by Source, 2020-2033
- 6.5.11. South Korea Liquid Biopsy Market Outlook, by Clinical Application , 2020-2033
- 6.5.12. South Korea Liquid Biopsy Market Outlook, by Indication , 2020-2033
- 6.5.13. India Liquid Biopsy Market Outlook, by Biomarker, 2020-2033
- 6.5.14. India Liquid Biopsy Market Outlook, by Source, 2020-2033
- 6.5.15. India Liquid Biopsy Market Outlook, by Clinical Application , 2020-2033
- 6.5.16. India Liquid Biopsy Market Outlook, by Indication , 2020-2033
- 6.5.17. Southeast Asia Liquid Biopsy Market Outlook, by Biomarker, 2020-2033
- 6.5.18. Southeast Asia Liquid Biopsy Market Outlook, by Source, 2020-2033
- 6.5.19. Southeast Asia Liquid Biopsy Market Outlook, by Clinical Application , 2020-2033
- 6.5.20. Southeast Asia Liquid Biopsy Market Outlook, by Indication , 2020-2033
- 6.5.21. Rest of SAO Liquid Biopsy Market Outlook, by Biomarker, 2020-2033
- 6.5.22. Rest of SAO Liquid Biopsy Market Outlook, by Source, 2020-2033
- 6.5.23. Rest of SAO Liquid Biopsy Market Outlook, by Clinical Application , 2020-2033
- 6.5.24. Rest of SAO Liquid Biopsy Market Outlook, by Indication , 2020-2033
- 6.6. BPS Analysis/Market Attractiveness Analysis
7. Latin America Liquid Biopsy Market Outlook, 2020-2033
- 7.1. Latin America Liquid Biopsy Market Outlook, by Biomarker, Value (US$ Bn), 2020-2033
- 7.1.1. Circulating Tumour Cells
- 7.1.2. Circulating Tumour DNA
- 7.1.3. Circulating free DNA
- 7.1.4. Circulating Cell free RNA
- 7.1.5. Exomes
- 7.1.6. Other
- 7.2. Latin America Liquid Biopsy Market Outlook, by Source, Value (US$ Bn), 2020-2033
- 7.2.1. Blood
- 7.2.2. Urine
- 7.2.3. Other
- 7.3. Latin America Liquid Biopsy Market Outlook, by Clinical Application , Value (US$ Bn), 2020-2033
- 7.3.1. Diagnosis & Screening
- 7.3.2. Treatment Selection
- 7.3.3. Treatment Monitoring
- 7.3.4. Recurrence Monitoring
- 7.4. Latin America Liquid Biopsy Market Outlook, by Indication , Value (US$ Bn), 2020-2033
- 7.4.1. Lung Cancer
- 7.4.2. Breast Cancer
- 7.4.3. Prostate Cancer
- 7.4.4. Colorectal Cancer
- 7.4.5. Other Cancers
- 7.4.6. Non-Oncology
- 7.5. Latin America Liquid Biopsy Market Outlook, by Country, Value (US$ Bn), 2020-2033
- 7.5.1. Brazil Liquid Biopsy Market Outlook, by Biomarker, 2020-2033
- 7.5.2. Brazil Liquid Biopsy Market Outlook, by Source, 2020-2033
- 7.5.3. Brazil Liquid Biopsy Market Outlook, by Clinical Application , 2020-2033
- 7.5.4. Brazil Liquid Biopsy Market Outlook, by Indication , 2020-2033
- 7.5.5. Mexico Liquid Biopsy Market Outlook, by Biomarker, 2020-2033
- 7.5.6. Mexico Liquid Biopsy Market Outlook, by Source, 2020-2033
- 7.5.7. Mexico Liquid Biopsy Market Outlook, by Clinical Application , 2020-2033
- 7.5.8. Mexico Liquid Biopsy Market Outlook, by Indication , 2020-2033
- 7.5.9. Argentina Liquid Biopsy Market Outlook, by Biomarker, 2020-2033
- 7.5.10. Argentina Liquid Biopsy Market Outlook, by Source, 2020-2033
- 7.5.11. Argentina Liquid Biopsy Market Outlook, by Clinical Application , 2020-2033
- 7.5.12. Argentina Liquid Biopsy Market Outlook, by Indication , 2020-2033
- 7.5.13. Rest of LATAM Liquid Biopsy Market Outlook, by Biomarker, 2020-2033
- 7.5.14. Rest of LATAM Liquid Biopsy Market Outlook, by Source, 2020-2033
- 7.5.15. Rest of LATAM Liquid Biopsy Market Outlook, by Clinical Application , 2020-2033
- 7.5.16. Rest of LATAM Liquid Biopsy Market Outlook, by Indication , 2020-2033
- 7.6. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Liquid Biopsy Market Outlook, 2020-2033
- 8.1. Middle East & Africa Liquid Biopsy Market Outlook, by Biomarker, Value (US$ Bn), 2020-2033
- 8.1.1. Circulating Tumour Cells
- 8.1.2. Circulating Tumour DNA
- 8.1.3. Circulating free DNA
- 8.1.4. Circulating Cell free RNA
- 8.1.5. Exomes
- 8.1.6. Other
- 8.2. Middle East & Africa Liquid Biopsy Market Outlook, by Source, Value (US$ Bn), 2020-2033
- 8.2.1. Blood
- 8.2.2. Urine
- 8.2.3. Other
- 8.3. Middle East & Africa Liquid Biopsy Market Outlook, by Clinical Application , Value (US$ Bn), 2020-2033
- 8.3.1. Diagnosis & Screening
- 8.3.2. Treatment Selection
- 8.3.3. Treatment Monitoring
- 8.3.4. Recurrence Monitoring
- 8.4. Middle East & Africa Liquid Biopsy Market Outlook, by Indication , Value (US$ Bn), 2020-2033
- 8.4.1. Lung Cancer
- 8.4.2. Breast Cancer
- 8.4.3. Prostate Cancer
- 8.4.4. Colorectal Cancer
- 8.4.5. Other Cancers
- 8.4.6. Non-Oncology
- 8.5. Middle East & Africa Liquid Biopsy Market Outlook, by Country, Value (US$ Bn), 2020-2033
- 8.5.1. GCC Liquid Biopsy Market Outlook, by Biomarker, 2020-2033
- 8.5.2. GCC Liquid Biopsy Market Outlook, by Source, 2020-2033
- 8.5.3. GCC Liquid Biopsy Market Outlook, by Clinical Application , 2020-2033
- 8.5.4. GCC Liquid Biopsy Market Outlook, by Indication , 2020-2033
- 8.5.5. South Africa Liquid Biopsy Market Outlook, by Biomarker, 2020-2033
- 8.5.6. South Africa Liquid Biopsy Market Outlook, by Source, 2020-2033
- 8.5.7. South Africa Liquid Biopsy Market Outlook, by Clinical Application , 2020-2033
- 8.5.8. South Africa Liquid Biopsy Market Outlook, by Indication , 2020-2033
- 8.5.9. Egypt Liquid Biopsy Market Outlook, by Biomarker, 2020-2033
- 8.5.10. Egypt Liquid Biopsy Market Outlook, by Source, 2020-2033
- 8.5.11. Egypt Liquid Biopsy Market Outlook, by Clinical Application , 2020-2033
- 8.5.12. Egypt Liquid Biopsy Market Outlook, by Indication , 2020-2033
- 8.5.13. Nigeria Liquid Biopsy Market Outlook, by Biomarker, 2020-2033
- 8.5.14. Nigeria Liquid Biopsy Market Outlook, by Source, 2020-2033
- 8.5.15. Nigeria Liquid Biopsy Market Outlook, by Clinical Application , 2020-2033
- 8.5.16. Nigeria Liquid Biopsy Market Outlook, by Indication , 2020-2033
- 8.5.17. Rest of Middle East Liquid Biopsy Market Outlook, by Biomarker, 2020-2033
- 8.5.18. Rest of Middle East Liquid Biopsy Market Outlook, by Source, 2020-2033
- 8.5.19. Rest of Middle East Liquid Biopsy Market Outlook, by Clinical Application , 2020-2033
- 8.5.20. Rest of Middle East Liquid Biopsy Market Outlook, by Indication , 2020-2033
- 8.6. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
- 9.1. Company Vs Segment Heatmap
- 9.2. Company Market Share Analysis, 2025
- 9.3. Competitive Dashboard
- 9.4. Company Profiles
- 9.4.1. Guardant Health, Inc.
- 9.4.1.1. Company Overview
- 9.4.1.2. Product Portfolio
- 9.4.1.3. Financial Overview
- 9.4.1.4. Business Strategies and Developments
- 9.4.2. Grail (Illumina, Inc.)
- 9.4.3. ANGLE plc
- 9.4.4. Hoffmann-La Roche Ltd.
- 9.4.5. Invitae Corporation
- 9.4.6. Myriad Genetics, Inc.
- 9.4.7. Qiagen N.V.
- 9.4.8. Exact Sciences Corporation
- 9.4.9. MDxHealth SA
- 9.4.10. Sysmex Inostics
- 9.4.1. Guardant Health, Inc.
10. Appendix
- 10.1. Research Methodology
- 10.2. Report Assumptions
- 10.3. Acronyms and Abbreviations
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.